

-2-

D27  
106. A method of treating Crohn's disease in a human comprising administering to the human an effective TNF-inhibiting amount of an anti-TNF chimeric antibody, wherein said anti-TNF chimeric antibody comprises a non-human variable region or a TNF-binding portion thereof and a human constant region.

107. The method of Claim 106 wherein the non-human variable region is of murine origin.

108. The method of Claim 106 wherein said anti-TNF chimeric antibody competitively inhibits binding of TNF to a monoclonal antibody selected from the group consisting of A2 or cA2.

Sub D3  
109. The method of Claim 106 wherein said anti-TNF chimeric antibody does not bind to one or more epitopes included in amino acids 11-13, 37-42, 4957 or 155-157 of SEQ ID NO.: 1 of hTNF.

110. A method of treating Crohn's disease in a human comprising administering to the human an effective TNF-inhibiting amount of an anti-TNF chimeric antibody, wherein said anti-TNF chimeric antibody competitively inhibits binding of TNF to a monoclonal antibody selected from the group consisting of A2 or cA2.

111. A method of treating Crohn's disease in a human comprising administering to the human an effective TNF-inhibiting amount of an anti-TNF chimeric antibody, wherein said anti-TNF chimeric antibody

-3-

*Sub D3*

binds to amino acids between 87-108 or both 59-80  
and 87-108 of SEQ ID NO.:1 of hTNF.

112. A method of treating Crohn's disease in a human  
comprising administering to the human an effective  
TNF-inhibiting amount of chimeric anti-TNF  
antibody cA2.

Claims 106-112 are pending. Entry of the Preliminary  
Amendment prior to examination of the application is  
respectfully requested and pursuant to the telephone  
conversation between Examiner Nisbet and the undersigned on  
December 1, 1995. This amendment is made to reduce issues  
on examination expedite prosecution. The application is now  
in condition for allowance. If the Examiner feels that a  
telephonic interview would facilitate examination, he is  
encouraged to telephone the undersigned at (617)861-6240.

Respectfully submitted,



Carolyn S. Elmore

Registration No. 37,567

Patent Agent

(617) 861-6240

Lexington, MA 02173

Dated: 12/5/95